	US 12,331,118 B2
	Humanized anti-human-PD-1 antibody and methods of using them for cancer treatment
Nicolas Poirier, Treillieres (FR); Caroline Mary, Sainte Pazanne (FR); Virginie Thepenier, Sainte Pazanne (FR); Aurore Morello, Saint Sebastien sur Loire (FR); and Sabrina Pengam, Sainte Luce sur Loire (FR)
Assigned to OSE IMMUNOTHERAPEUTICS, Nantes (FR)
Filed by OSE IMMUNOTHERAPEUTICS, Nantes (FR)
Filed on Jun. 2, 2022, as Appl. No. 17/830,381.
Application 17/830,381 is a continuation of application No. 17/414,967, granted, now 11,352,430, previously published as PCT/EP2019/085776, filed on Dec. 17, 2019.
Claims priority of application No. 18306801 (EP), filed on Dec. 21, 2018.
Prior Publication US 2022/0332826 A1, Oct. 20, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01)

CPC C07K 16/2818 (2013.01) [A61K 45/06 (2013.01); A61P 35/00 (2018.01); A61K 2039/505 (2013.01)]

9 Claims

1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a humanized monoclonal anti-human-PD-1 antibody or an antigen-binding fragment thereof comprising:

(i) a heavy chain variable domain comprising HCDR1 comprising SEQ ID NO: 1, HCDR2 comprising SEQ ID NO: 2 and HCDR3 comprising SEQ ID NO: 9, and

(ii) a light chain variable domain comprising LCDR1 comprising SEQ ID NO: 12, LCDR2 comprising SEQ ID NO: 13 and LCDR3 comprising SEQ ID NO: 14.

6. A method of treating cancer in a subject comprising administering a composition according to claim 1 to a subject having cancer, said cancer being selected from the group consisting of malignant mesothelioma, colorectal cancer and hepatocellular carcinoma.